share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  04/16 17:31

Moomoo AI 已提取核心信息

On April 11, 2024, Conduit Pharmaceuticals Inc. announced that its previously issued unaudited financial statements for the first three quarters of 2023 should not be relied upon and will require restatement. The decision, made after discussions with the company's advisors and its independent accounting firm Marcum LLP, pertains to the incorrect accounting treatment of certain legal expenses related to a business combination and concurrent private placement financing. These expenses, which should have been capitalized, were instead expensed, leading to an understatement of net income and prepaid expenses, and an overstatement of additional paid-in capital. The necessary adjustments will reduce legal expenses reported in the first, second, and third quarters of 2023 by $493,000, $402,000, and $639,000, respectively. Conduit Pharmaceuticals plans to include the restated financials and adjustments in its upcoming annual report on Form 10-K. The company's management and Audit Committee have discussed these issues with Marcum LLP, which will also provide a letter to the SEC regarding the restatement.
On April 11, 2024, Conduit Pharmaceuticals Inc. announced that its previously issued unaudited financial statements for the first three quarters of 2023 should not be relied upon and will require restatement. The decision, made after discussions with the company's advisors and its independent accounting firm Marcum LLP, pertains to the incorrect accounting treatment of certain legal expenses related to a business combination and concurrent private placement financing. These expenses, which should have been capitalized, were instead expensed, leading to an understatement of net income and prepaid expenses, and an overstatement of additional paid-in capital. The necessary adjustments will reduce legal expenses reported in the first, second, and third quarters of 2023 by $493,000, $402,000, and $639,000, respectively. Conduit Pharmaceuticals plans to include the restated financials and adjustments in its upcoming annual report on Form 10-K. The company's management and Audit Committee have discussed these issues with Marcum LLP, which will also provide a letter to the SEC regarding the restatement.
2024年4月11日，Conduit Pharmicals Inc.宣布，不应依赖其先前发布的2023年前三个季度的未经审计的财务报表，将需要重报。该决定是在与公司的顾问及其独立会计师事务所Marcum LLP讨论后做出的，涉及对与企业合并和并行私募融资相关的某些法律费用的错误会计处理。这些本应资本化的支出却被列为支出，导致净收入和预付费用被低估，并夸大了额外的实收资本。必要的调整将使2023年第一、第二和第三季度报告的法律费用分别减少49.3万美元、40.2万美元和63.9万美元。Conduit Pharmicals计划在即将发布的10-K表年度报告中纳入重报的财务状况和调整。该公司的管理和审计委员会已与Marcum LLP讨论了这些问题，后者还将就重报事宜致函美国证券交易委员会。
2024年4月11日，Conduit Pharmicals Inc.宣布，不应依赖其先前发布的2023年前三个季度的未经审计的财务报表，将需要重报。该决定是在与公司的顾问及其独立会计师事务所Marcum LLP讨论后做出的，涉及对与企业合并和并行私募融资相关的某些法律费用的错误会计处理。这些本应资本化的支出却被列为支出，导致净收入和预付费用被低估，并夸大了额外的实收资本。必要的调整将使2023年第一、第二和第三季度报告的法律费用分别减少49.3万美元、40.2万美元和63.9万美元。Conduit Pharmicals计划在即将发布的10-K表年度报告中纳入重报的财务状况和调整。该公司的管理和审计委员会已与Marcum LLP讨论了这些问题，后者还将就重报事宜致函美国证券交易委员会。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间